Preclinical evaluation of psilocybin and related compounds: Inhibition of cytochrome P450 isoforms

Sa1731 A PILOT STUDY OF OPEN-LABEL PSILOCYBIN-ASSISTED THERAPY IN TREATMENT-REFRACTORY IBS

SAT-219 Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models

6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy

Cytochrome P450 Inhibition by Psilocybin and Psilocin: A Combined Molecular Dynamics and Enzymatic Screening Study

Role of Psychological support in sustaining Antidepressants effects in Psilocybin - Assisted Clinical

Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review.

Psychedelic-assisted therapy (PAT) has demonstrated substantial efficacy across a range of mental disorders. However, heterogeneity between patients confers differential responsiveness. This systematic review aims to explore factors which may predict therapeutic responses to PAT. A systematic search was performed from inception through to March 2024 and stud...

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

ImportancePsilocybin shows promise in treating depression, although limitations of previous research warrant further research.ObjectiveTo investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD).Design, setting, and participantsThis was a 2-center, triple-blinded (investigator, particip...

Enlightenment in a Pill-Testing the Efficacy of Psilocybin.

Trip killers: Addressing a critical knowledge gap in psychedelic research.

Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a "bad trip." Bad trips represent a potentially volatile, erratic, and dangerous situation, whic...

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial.

ImportanceCocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment.ObjectiveTo evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abst...

Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical Appraisal.

Olanzapine for young people with anorexia nervosa: a synopsis of the main results from the OPEN open-label feasibility study.

In clinical practice, olanzapine is commonly used in young people with anorexia nervosa, although the underpinning evidence-base is limited. However, its efficacy, tolerability, acceptability and adherence rate, and the patients', carers' and clinicians' views of olanzapine treatment are unclear. This synopsis article summarises the methods and results of th...

Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major Depression: A Randomized Clinical Trial.

ImportancePsilocybin has been proposed as a rapid-acting antidepressant (onset 6 weeks), but evidence from randomized clinical trials remains limited, particularly in the broader major depressive disorder (MDD) population.ObjectiveTo assess short-term and long-term antidepressant effects of psilocybin therapy in patients with MDD.Design, setting, and partici...

New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants.

BackgroundPsilocybe mushrooms (psilocybin/psilocin [PSI/PSC]) and ayahuasca (N,N-dimethyltryptamine [DMT]) are hallucinogenic serotonergic agonists. Pregnant and lactating women are frequently omitted from clinical studies; hence minimal developmental/reproductive/neurotoxicity (DART/DNT) and endocrine disruption (ED) data in humans are available. Hallucinog...

Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence.

BackgroundDepression is a prevalent comorbidity in cancer, yet conventional treatments show inconsistent efficacy. This review sought to provide a mechanism-based framework for managing cancer-related depression by exploring its unique pathophysiology and evaluating promising pharmacotherapies based on their alignment with these biological pathways. This nar...

Synthesis of Amines for Active Pharmaceutical Ingredients Using the Whole-Cell Factory Saccharomyces Cerevisae.

Whole-cell biocatalysis offers a sustainable alternative to traditional chemical synthesis for producing pharmaceutically relevant, often chiral, amines and amino acids. Saccharomyces cerevisiae has emerged as a privileged microbial chassis due to its robustness, ease of genetic manipulation, and GRAS status. This concise review summarizes recent advances in...

Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake.

Detecting psilocybin use is challenging because it rapidly converts to its psychoactive metabolite psilocin, and both compounds are unstable in blood. Bufotenin, a structural isomer of psilocin, may exhibit comparable instability in blood. For reliable detection, we developed and validated an LC-MS/MS method to simultaneously quantify psilocin, bufotenin, an...

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption.

Mystical experiences are characterized by a profound sense of interconnectedness and transcendence of ordinary reality. These experiences can facilitate feelings of connectedness with oneself and others and have been documented as leading to significant positive changes in thoughts, emotions, and behavior. The purpose of the present study was to evaluate the...

Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive...